Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma
Figlin, Robert A., Tannir, Nizar M., Uzzo, Robert G., Tykodi, Scott S., Chen, David Y.T., Master, Viraj, Kapoor, Anil, Vaena, Daniel, Lowrance, William T., DeBenedette, Mark, Gamble, Alicia, Plachco,Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.ccr-19-2427
Date:
February, 2020
File:
PDF, 2.42 MB
2020